LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for ...

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating ...

Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its strategic reboot. The company will henceforth be known as Whitehawk ...

Aadi Bioscience’s Fyarro is on track to fail a phase 2 solid tumor trial, leading the biotech to halt the study and lay off 80% of its R&D workforce.. The company had been investigating the ...

Aadi to Sell FYARRO for $100 Million, Cumulative Capital Expected to Fund Operations into Late 2028. In a separate agreement, KAKEN Pharmaceutical Co., Ltd., ...

Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for ...

Aadi Bioscience inks $44 million deal for exclusive rights to three preclinical ADC programs. Aadi secures $100 million in PIPE financing, selling 21.6 million shares at $2.40 each to support its ...

About Aadi and ABI-009 Aadi is a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of ABRAXANE®, ABI-009 and the nab® technology platform.

Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and ...

Aadi BioScience (AADI) shares plunged 57% after-hours following disappointing results from a registrational study for its anti-tumor drug nab-sirolimus. Read more here.